Tongzhi Wu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7974208/tongzhi-wu-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92 papers	1,455 citations	23 h-index	35 g-index
109 ext. papers	1,868 ext. citations	6 avg, IF	4.8 L-index

#	Paper	IF	Citations
92	Muscle strength and prediabetes progression and regression in middle-aged and older adults: a prospective cohort study.. *Journal of Cachexia, Sarcopenia and Muscle*, **2022**,	10.3	1
91	Measurement of plasma glucagon in humans - a shift in the performance of a current commercially available RIA kit.. *Diabetes, Obesity and Metabolism*, **2022**,	6.7	1
90	Effects of ileal glucose infusion on enteropancreatic hormone secretion in humans: relationship to glucose absorption.. *Metabolism: Clinical and Experimental*, **2022**, 131, 155198	12.7	0
89	Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.. *Diabetes Therapy*, **2022**, 1	3.6	0
88	Investigation of the association between lens autofluorescence ratio and diabetes: a cross-sectional study.. *Photodiagnosis and Photodynamic Therapy*, **2022**, 102888	3.5	
87	Is imaging-based muscle quantity associated with risk of diabetes? A meta-analysis of cohort studies. *Diabetes Research and Clinical Practice*, **2022**, 109939	7.4	
86	Does objectively measured light-intensity physical activity reduce the risk of cardiovascular mortality? A meta-analysis. *European Heart Journal Quality of Care & Clinical Outcomes*, **2021**, 7, 496-504	4.6	4
85	Changes in objectively-measured physical capability over 4-year, risk of diabetes, and glycemic control in older adults: the China Health and Retirement Longitudinal Study.. *Diabetes Research and Clinical Practice*, **2021**, 109186	7.4	0
84	Plasma GLP-1 response to oral and intraduodenal nutrients in health and type 2 diabetes - impact on gastric emptying. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	1
83	Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518. *Diabetes Care*, **2021**, 44, e194-e195	14.6	1
82	Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease. *Nutrients*, **2021**, 13,	6.7	22
81	Response to Dahl et al.: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2411-2413	6.7	1
80	Changes in creatinine-to-cystatin C ratio over 4 years, risk of diabetes, and cardiometabolic control: The China Health and Retirement Longitudinal Study. *Journal of Diabetes*, **2021**, 13, 1025-1033	3.8	0
79	Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis. *Diabetes, Obesity and Metabolism*, **2021**, 23, 136-146	6.7	5
78	Gastric emptying in health and type 2 diabetes: An evaluation using a 75 g oral glucose drink. *Diabetes Research and Clinical Practice*, **2021**, 171, 108610	7.4	3
77	Spontaneous or Deliberate: Effects of Acute Variations in Glycemia on Gastric Emptying in Type 1 Diabetes. *Diabetes Care*, **2021**, 44, 316-318	14.6	1
76	Is estimated cardiorespiratory fitness an effective predictor for cardiovascular and all-cause mortality? A meta-analysis. *Atherosclerosis*, **2021**, 330, 22-28	3.1	5

75	Potential for Gut Peptide-Based Therapy in Postprandial Hypotension. *Nutrients*, **2021**, 13,	6.7	1
74	Lactate and Myocadiac Energy Metabolism. *Frontiers in Physiology*, **2021**, 12, 715081	4.6	6
73	Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. *Diabetes Care*, **2020**, 43, 1813-1821	14.6	11
72	Effects of Proximal and Distal Enteral Glucose Infusion on Cardiovascular Response in Health and Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	3
71	Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. *Nutrients*, **2020**, 12,	6.7	4
70	Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations. *Diabetes, Obesity and Metabolism*, **2020**, 22, 788-797	6.7	20
69	A Multiplexed Microfluidic Platform toward Interrogating Endocrine Function: Simultaneous Sensing of Extracellular Ca and Hormone. *ACS Sensors*, **2020**, 5, 490-499	9.2	2
68	Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2020**, 22, 383-392	6.7	6
67	Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2020**, 22, 51-58	6.7	8
66	Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. *Diabetes, Obesity and Metabolism*, **2020**, 22, 141-148	6.7	24
65	The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. *Acta Diabetologica*, **2020**, 57, 583-587	3.9	1
64	Intragastric administration of the bitter tastant quinine lowers the glycemic response to a nutrient drink without slowing gastric emptying in healthy men. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2020**, 318, R263-R273	3.2	11
63	Disparities in gastric emptying and postprandial glycaemia between Han Chinese and Caucasians with type 2 diabetes. *Diabetes Research and Clinical Practice*, **2020**, 159, 107951	7.4	4
62	Statins and glycaemic control in type 2 diabetes: Are bile acids relevant?. *British Journal of Clinical Pharmacology*, **2020**, 86, 2538-2539	3.8	
61	Gastrointestinal autonomic neuropathy in diabetes. *Autonomic Neuroscience: Basic and Clinical*, **2020**, 229, 102718	2.4	5
60	Role of intestinal glucose absorption in glucose tolerance. *Current Opinion in Pharmacology*, **2020**, 55, 116-124	5.1	4
59	Comparative Effects of Intraduodenal Glucose and Fat Infusion on Blood Pressure and Heart Rate in Type 2 Diabetes. *Frontiers in Nutrition*, **2020**, 7, 582314	6.2	1
58	Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin. *Pharmaceuticals*, **2020**, 13,	5.2	1

57	Glucagon-like peptide-1 receptor agonists and the appropriate measurement of gastric emptying. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2504-2506	6.7	8
56	Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation. *Pharmaceutics*, **2020**, 12,	6.4	12
55	Diabetes and the Gastrointestinal Tract **2020**, 9-12		
54	Objectively-Measured Light-Intensity Physical Activity and Risk of Cancer Mortality: A Meta-analysis of Prospective Cohort Studies. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1067-1073	4	7
53	Effects of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility, Plasma Cholecystokinin, and Energy Intake in Healthy Men. *Journal of Neurogastroenterology and Motility*, **2019**, 25, 413-422	4.4	8
52	Gastric Emptying in Patients With Well-Controlled Type 2 Diabetes Compared With Young and Older Control Subjects Without Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 3311-3319	5.6	26
51	Longitudinal evaluation of gastric emptying in type 2 diabetes. *Diabetes Research and Clinical Practice*, **2019**, 154, 27-34	7.4	5
50	Efficacy of Co-administration of Liuwei Dihuang Pills and Ginkgo Biloba Tablets on Albuminuria in Type 2 Diabetes: A 24-Month, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *Frontiers in Endocrinology*, **2019**, 10, 100	5.7	13
49	Comparative Effects of Proximal and Distal Small Intestinal Glucose Exposure on Glycemia, Incretin Hormone Secretion, and the Incretin Effect in Health and Type 2 Diabetes. *Diabetes Care*, **2019**, 42, 520-528	14.6	24
48	Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 6201-6206	5.6	5
47	The Effects of a Whey Protein and Guar Gum-Containing Preload on Gastric Emptying, Glycaemia, Small Intestinal Absorption and Blood Pressure in Healthy Older Subjects. *Nutrients*, **2019**, 11,	6.7	3
46	A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial. *Diabetes, Obesity and Metabolism*, **2019**, 21, 930-938	6.7	16
45	Title: Differentiating the effects of whey protein and guar gum preloads on postprandial glycemia in type 2 diabetes. *Clinical Nutrition*, **2019**, 38, 2827-2832	5.9	11
44	Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1158-1167	6.7	27
43	Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1251-1254	6.7	9
42	Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2019**, 21, 640-647	6.7	20
41	Augmented capacity for peripheral serotonin release in human obesity. *International Journal of Obesity*, **2018**, 42, 1880-1889	5.5	37
40	Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957. *Diabetes Care*, **2018**, 41, e27-e28	14.6	

39	Comparative effects of small intestinal glucose on blood pressure, heart rate, and noradrenaline responses in obese and healthy subjects. *Physiological Reports*, **2018**, 6, e13610	2.6	1
38	Gut Mechanisms Linking Intestinal Sweet Sensing to Glycemic Control. *Frontiers in Endocrinology*, **2018**, 9, 741	5.7	14
37	Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 4409-4418	5.6	15
36	Role of Intestinal Bitter Sensing in Enteroendocrine Hormone Secretion and Metabolic Control. *Frontiers in Endocrinology*, **2018**, 9, 576	5.7	28
35	Gastric Emptying and the Personalized Management of Type 1 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 3503-3506	5.6	4
34	Effects of intraduodenal administration of the artificial sweetener sucralose on blood pressure and superior mesenteric artery blood flow in healthy older subjects. *American Journal of Clinical Nutrition*, **2018**, 108, 156-162	7	4
33	Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes. *Diabetes and Vascular Disease Research*, **2017**, 14, 59-63	3.3	12
32	Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes. *Diabetes Care*, **2017**, 40, 702-705	14.6	11
31	New insights into the anti-diabetic actions of metformin: from the liver to the gut. *Expert Review of Gastroenterology and Hepatology*, **2017**, 11, 157-166	4.2	30
30	Comparative effects of intraduodenal fat and glucose on the gut-incretin axis in healthy males. *Peptides*, **2017**, 95, 124-127	3.8	14
29	Whey Protein and Diabetes **2017**, 197-209		2
28	Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2017**, 19, 290-293	6.7	33
27	Incretins. *Handbook of Experimental Pharmacology*, **2016**, 233, 137-71	3.2	39
26	The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. *Diabetes*, **2016**, 65, 269-75	0.9	42
25	Inter-regulation of gastric emptying and incretin hormone secretion: implications for postprandial glycemic control. *Biomarkers in Medicine*, **2016**, 10, 1167-1179	2.3	14
24	Regional specificity of the gut-incretin response to small intestinal glucose infusion in healthy older subjects. *Peptides*, **2016**, 86, 126-132	3.8	3
23	A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 511-7	14.6	55
22	Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. *American Journal of Clinical Nutrition*, **2016**, 103, 66-70	7	74

21	Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release, and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes: A randomised controlled trial. *Nutrition*, **2016**, 32, 553-9	4.8	6
20	Comparative Effects of Bile Diversion and Duodenal-Jejunal Bypass on Glucose and Lipid Metabolism in Male Diabetic Rats. *Obesity Surgery*, **2016**, 26, 1565-75	3.7	7
19	Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 4769-4778	5.6	12
18	Bile acid profiles in diabetic (db/db) mice and their wild type littermates. *Journal of Pharmaceutical and Biomedical Analysis*, **2016**, 131, 473-481	3.5	15
17	DPP-4 Inhibition and the Known Unknown. *Diabetes*, **2016**, 65, 2124-6	0.9	4
16	Whey protein: The "whey" forward for treatment of type 2 diabetes?. *World Journal of Diabetes*, **2015**, 6, 1274-84	4.7	42
15	Performance of Fasting Plasma Glucose and Postprandial Urine Glucose in Screening for Diabetes in Chinese High-risk Population. *Chinese Medical Journal*, **2015**, 128, 3270-5	2.9	5
14	Glucose absorption in small intestinal diseases. *Expert Review of Gastroenterology and Hepatology*, **2014**, 8, 301-12	4.2	14
13	Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?. *Diabetes Research and Clinical Practice*, **2014**, 106, e3-6	7.4	47
12	Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. *Diabetes*, **2014**, 63, 2776-87	0.9	35
11	Changes in meal composition and duration affect postprandial endothelial function in healthy humans. *American Journal of Physiology - Renal Physiology*, **2014**, 307, G1191-7	5.1	8
10	INS-1 cells inhibit the production of extracellular matrix from pancreatic stellate cells. *Journal of Molecular Histology*, **2014**, 45, 321-7	3.3	6
9	Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes. *Diabetes*, **2013**, 62, 3532-41	0.9	78
8	Gut motility and enteroendocrine secretion. *Current Opinion in Pharmacology*, **2013**, 13, 928-34	5.1	49
7	Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E718-22	5.6	60
6	Artificial sweeteners have no effect on gastric emptying, glucagon-like peptide-1, or glycemia after oral glucose in healthy humans. *Diabetes Care*, **2013**, 36, e202-3	14.6	43
5	Effects of intraduodenal glutamine on incretin hormone and insulin release, the glycemic response to an intraduodenal glucose infusion, and antropyloroduodenal motility in health and type 2 diabetes. *Diabetes Care*, **2013**, 36, 2262-5	14.6	32
4	Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. *Diabetes Care*, **2013**, 36, 1913-8	14.6	40

3	Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. *American Journal of Clinical Nutrition*, **2012**, 95, 78-83	7	113
2	Dietary effects on incretin hormone secretion. *Vitamins and Hormones*, **2010**, 84, 81-110	2.5	41
1	Sensing Intra- and Extra-Cellular Ca2+ in the Islet of Langerhans. *Advanced Functional Materials*,2106020	15.6	